- Results from the phase 2 CATALINA study using NGM621 for the treatment of patients with Geographic Atrophy are expected in the 2nd half of 2022.
- Results from a phase 1/2 study using NGM707 for the treatment of patients with advanced cancer are expected in the 2nd half of 2022.
- Results from the phase 2b ALPINE4 study using aldafermin for the treatment of patients with compensated NASH cirrhosis are expected 1st half of 2023.
- NGM Biopharmaceuticals had $329.8 million in cash as of March 31, 2022. It believes it has enough cash to fund its operations for at least the next 12 months.
For further details see:
NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022